201 related articles for article (PubMed ID: 22120252)
1. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage.
Soppi V; Karamanakos PN; Koivisto T; Kurki MI; Vanninen R; Jaaskelainen JE; Rinne J
World Neurosurg; 2012 Jul; 78(1-2):101-9. PubMed ID: 22120252
[TBL] [Abstract][Full Text] [Related]
2. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
Schmid-Elsaesser R; Kunz M; Zausinger S; Prueckner S; Briegel J; Steiger HJ
Neurosurgery; 2006 Jun; 58(6):1054-65; discussion 1054-65. PubMed ID: 16723884
[TBL] [Abstract][Full Text] [Related]
3. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration.
Kronvall E; Undrén P; Romner B; Säveland H; Cronqvist M; Nilsson OG
J Neurosurg; 2009 Jan; 110(1):58-63. PubMed ID: 18847340
[TBL] [Abstract][Full Text] [Related]
4. Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].
Hänggi D; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Macdonald RL;
Neurocrit Care; 2019 Feb; 30(1):88-97. PubMed ID: 30014184
[TBL] [Abstract][Full Text] [Related]
5. Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.
Ehlert A; Schmidt C; Wölfer J; Manthei G; Jacobs AH; Brüning R; Heindel W; Ringelstein EB; Stummer W; Pluta RM; Hesselmann V
J Neurosurg; 2016 Jan; 124(1):51-8. PubMed ID: 26162034
[TBL] [Abstract][Full Text] [Related]
6. NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage.
Hänggi D; Etminan N; Macdonald RL; Steiger HJ; Mayer SA; Aldrich F; Diringer MN; Hoh BL; Mocco J; Strange P; Faleck HJ; Miller M
Neurocrit Care; 2015 Oct; 23(2):274-84. PubMed ID: 25678453
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]).
Hänggi D; Etminan N; Aldrich F; Steiger HJ; Mayer SA; Diringer MN; Hoh BL; Mocco J; Faleck HJ; Macdonald RL;
Stroke; 2017 Jan; 48(1):145-151. PubMed ID: 27932607
[TBL] [Abstract][Full Text] [Related]
8. Effects of 14 Versus 21 Days of Nimodipine Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients.
Cho S; Bales J; Tran TK; Korab G; Khandelwal N; Joffe AM
Ann Pharmacother; 2016 Sep; 50(9):718-24. PubMed ID: 27273676
[TBL] [Abstract][Full Text] [Related]
9. Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage.
Carlson AP; Hänggi D; Wong GK; Etminan N; Mayer SA; Aldrich F; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Bleck T; Grubb R; Miller M; Suarez JI; Proskin HM; Macdonald RL;
Stroke; 2020 Apr; 51(4):1142-1149. PubMed ID: 32138631
[TBL] [Abstract][Full Text] [Related]
10. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
van den Bergh WM; Mees SM; Rinkel GJ
Neurosurgery; 2006 Nov; 59(5):E1152; author reply E1152. PubMed ID: 17143226
[No Abstract] [Full Text] [Related]
11. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.
Haley EC; Kassell NF; Apperson-Hansen C; Maile MH; Alves WM
J Neurosurg; 1997 Mar; 86(3):467-74. PubMed ID: 9046304
[TBL] [Abstract][Full Text] [Related]
12. Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage.
Hajizadeh Barfejani A; Rabinstein AA; Wijdicks EFM; Clark SL
J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2155-2158. PubMed ID: 31103551
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study.
Westermaier T; Stetter C; Vince GH; Pham M; Tejon JP; Eriskat J; Kunze E; Matthies C; Ernestus RI; Solymosi L; Roosen K
Crit Care Med; 2010 May; 38(5):1284-90. PubMed ID: 20228677
[TBL] [Abstract][Full Text] [Related]
14. Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
Sandow N; Diesing D; Sarrafzadeh A; Vajkoczy P; Wolf S
Neurocrit Care; 2016 Aug; 25(1):29-39. PubMed ID: 26690937
[TBL] [Abstract][Full Text] [Related]
15. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study.
Soppi V; Kokki H; Koivisto T; Lehtonen M; Helin-Tanninen M; Lehtola S; Rinne J
Eur J Clin Pharmacol; 2007 Apr; 63(4):355-61. PubMed ID: 17318527
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Cho WS; Kang HS; Kim JE; Kwon OK; Oh CW; Son YJ; Know BJ; Jung C; Hang MH
Interv Neuroradiol; 2011 Jun; 17(2):169-78. PubMed ID: 21696654
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of Cytochrome P450 of Nimodipine Metabolism After Aneurysmal Subarachnoid Hemorrhage.
Peacock SH; James C; Turnbull MT; Cowart JB; Reid JM; Freeman WD
J Neurosci Nurs; 2019 Oct; 51(5):238-242. PubMed ID: 31469704
[TBL] [Abstract][Full Text] [Related]
18. Impact of Early Versus Late Intravenous Followed by Oral Nimodipine Treatment on the Occurrence of Delayed Cerebral Ischemia Among Patients With Aneurysm Subarachnoid Hemorrhage.
Samseethong T; Suansanae T; Veerasarn K; Liengudom A; Suthisisang C
Ann Pharmacother; 2018 Nov; 52(11):1061-1069. PubMed ID: 29783859
[TBL] [Abstract][Full Text] [Related]
19. Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics.
Vázquez-Medina A; Turnbull MT; James CL; Cowart JB; Lesser E; Carter RE; Ross OA; Miller DA; Meschia JF; De Jesús Espinosa A; Weinshilboum R; Freeman WD
Pharmacogenomics J; 2024 Jun; 24(4):19. PubMed ID: 38890281
[TBL] [Abstract][Full Text] [Related]
20. Resistant vasospasm in subarachnoid hemorrhage treated with continuous intraarterial nimodipine infusion.
Doukas A; Petridis AK; Barth H; Jansen O; Maslehaty H; Mehdorn HM
Acta Neurochir Suppl; 2011; 112():93-6. PubMed ID: 21691994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
